CLINICAL TRIALS PROFILE FOR AMIFOSTINE

All Clinical Trials for AMIFOSTINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002643 ↗	Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor	Completed	Children's Cancer Group	Phase 2	1995-04-01	Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00002643 ↗	Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor	Completed	National Cancer Institute (NCI)	Phase 2	1995-04-01	Phase II trial to study the effectiveness of combination chemotherapy in treating patients with newly diagnosed metastatic Ewing's sarcoma or primitive neuroectodermal tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
NCT00003048 ↗	Amifostine in Treating Patients With Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 2	1997-06-05	RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
NCT00003048 ↗	Amifostine in Treating Patients With Myelodysplastic Syndrome	Completed	M.D. Anderson Cancer Center	Phase 2	1997-06-05	RATIONALE: Amifostine may improve blood counts in patients with myelodysplastic syndrome. PURPOSE: Phase II trial to study the effectiveness of amifostine in treating patients with myelodysplastic syndrome.
NCT00003068 ↗	High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer	Completed	University of Arizona	Phase 2	1997-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose mitoxantrone, thiotepa, and cyclophosphamide plus autologous peripheral stem cell transplantation and amifostine in treating patients with primary, locally advanced, or stage IV breast cancer.
NCT00003072 ↗	Combination Chemotherapy in Treating Patients With Metastatic Ovarian Cancer or Non-small Cell Lung Cancer	Completed	University of California, San Francisco	Phase 2	1997-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. PURPOSE: Randomized phase II double-blinded trial to study the effectiveness of paclitaxel and carboplatin given with either amifostine or placebo in patients with metastatic stage III or stage IV ovarian cancer or metastatic stage III or stage IV non-small cell lung cancer.
NCT00003089 ↗	Chemotherapy, Amifostine, and Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer	Completed	Sidney Kimmel Cancer Center at Thomas Jefferson University	Phase 2	1997-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of paclitaxel, carboplatin, amifostine, and radiation therapy in treating patients who have unresectable locally advanced or partially resected non-small cell lung cancer.

Clinical Trial Conditions for AMIFOSTINE

Condition Name

Condition Name for AMIFOSTINE
Intervention	Trials
Drug/Agent Toxicity by Tissue/Organ	19
Head and Neck Cancer	16
Lung Cancer	14
Radiation Toxicity	10

Condition MeSH

Condition MeSH for AMIFOSTINE
Intervention	Trials
Drug-Related Side Effects and Adverse Reactions	19
Head and Neck Neoplasms	17
Lung Neoplasms	12
Radiation Injuries	10

Clinical Trial Locations for AMIFOSTINE

Trials by Country

Trials by Country for AMIFOSTINE
Location	Trials
United States	362
Canada	27
France	8
Australia	6
China	4

Trials by US State

Trials by US State for AMIFOSTINE
Location	Trials
California	20
Illinois	18
Pennsylvania	16
Ohio	15
Florida	13

Clinical Trial Progress for AMIFOSTINE

Clinical Trial Phase

Clinical Trial Phase for AMIFOSTINE
Clinical Trial Phase	Trials
Phase 4	4
Phase 3	11
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for AMIFOSTINE
Clinical Trial Phase	Trials
Completed	52
Unknown status	15
Terminated	10

Clinical Trial Sponsors for AMIFOSTINE

Sponsor Name

Sponsor Name for AMIFOSTINE
Sponsor	Trials
National Cancer Institute (NCI)	33
MedImmune LLC	10
Dana-Farber Cancer Institute	6

Sponsor Type

Sponsor Type for AMIFOSTINE
Sponsor	Trials
Other	89
NIH	33
Industry	18